• Jeremy R Beitler, Ewan C Goligher, Matthieu Schmidt, Peter M Spieth, Alberto Zanella, Ignacio Martin-Loeches, Carolyn S Calfee, Alexandre B Cavalcanti, and ARDSne(x)t Investigators.
• Division of Pulmonary and Critical Care Medicine, University of California, San Diego, 200 West Arbor Drive, #8409, San Diego, CA, 92103, USA. jbeitler@ucsd.edu.
• Intensive Care Med. 2016 May 1; 42 (5): 756-767.

AbstractIn the last 20 years, survival among patients with acute respiratory distress syndrome (ARDS) has increased substantially with advances in lung-protective ventilation and resuscitation. Building on this success, personalizing mechanical ventilation to patient-specific physiology for enhanced lung protection will be a top research priority for the years ahead. However, the ARDS research agenda must be broader in scope. Further understanding of the heterogeneous biology, from molecular to mechanical, underlying early ARDS pathogenesis is essential to inform therapeutic discovery and tailor treatment and prevention strategies to the individual patient. The ARDSne(x)t research agenda for the next 20 years calls for bringing personalized medicine to ARDS, asking simultaneously both whether a treatment affords clinically meaningful benefit and for whom. This expanded scope necessitates standard acquisition of highly granular biological, physiological, and clinical data across studies to identify biologically distinct subgroups that may respond differently to a given intervention. Clinical trials will need to consider enrichment strategies and incorporate long-term functional outcomes. Tremendous investment in research infrastructure and global collaboration will be vital to fulfilling this agenda.

17 keywords...

hide…